Variant Creutzfeldt-Jakob disease

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 175-180

  Ironside, J W ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Blood; Haemophilia; Plasma; Prion; Transfusion; Variant CJD

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; METHIONINE; PRION PROTEIN; VALINE;

BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; CODON; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DNA POLYMORPHISM; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; GEOGRAPHIC DISTRIBUTION; HEMOPHILIA; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; INCUBATION TIME; INFECTION RISK; LYMPHOID TISSUE; MORTALITY; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SPLEEN; UNITED KINGDOM; VARIANT CREUTZFELDT JAKOB DISEASE;

BLOOD COAGULATION FACTORS; BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; DISEASE TRANSMISSION, INFECTIOUS; GREAT BRITAIN; HEMOPHILIA A; HUMANS; PRION DISEASES;

EID: 77955034938     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02317.x     Document Type: Review

References (38)

1. Ironside JW. Creutzfeldt-Jakob disease. Brain Pathol 1996, 6:379-88.
2. Prusiner SB. Prions. Proc Nat Acad Sci USA 1998, 95:13363-83.
3. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-44.
4. Infection Control Guidelines for Transmissible Spongiform Encephalopathies 2000, Geneva, World Health Organisation
5. Brown P, Cathala F, Raubertas RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987, 37:895-904.
6. Alperovitch A, Zerr I, Pocchiari M. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999, 353:1673-4.
7. Smith PG, Bradley R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull 2003, 66:185-98.
8. Will RG, Ironside JW, Zeidler M. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347:921-5.
9. Ironside JW, McCardle L, Horsburgh A, Lim Z, Head MW. Pathological diagnosis of variant Creutzfeldt-Jakob disease. APMIS 2002, 110:79-87.
10. Kaski D, Mead S, Hyare H. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 2009, 374:2128.
11. Bruce ME, Will RG, Ironside JW. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997, 389:498-501.
12. Scott MR, Will R, Ironside J. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 1999, 96:15137-42.
13. Ward HJ, Everingtom D, Cousens SN. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol 2006, 59:111-20.
14. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001, 358:208-9.
15. Hilton DA, Ghani AC, Conyers L. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004, 203:733-9.
16. Turner ML, Ironside JW. New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. Blood Rev 1998, 12:255-68.
17. Houston F, McCutcheon S, Goldmann W. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008, 112:4739-45.
18. Clewley JP, Kelly CM, Andrews N. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. Br Med J 2009, 338:b1442.
19. Peden A, McCardle L, Head MW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010, 16:296-304.
20. Holada K, Vostal JG, Therisen PW. Scrapie infectivity in hamster blood is not associated with platelets. J Virol 2002, 76:4649-60.
21. Cervenakova L, Yakovleva O, McKenzie C. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003, 43:1687-94.
22. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006, 91:221-30.
23. Wroe SJ, Pal S, Siddique D. Clinical presentation and pre-mortem diagnosis of Creutzfeldt-Jakob disease associated with blood transfusion. Lancet 2006, 368:2061-7.
24. Head MW, Yull H, Ritchie DL, Bishop MT, Ironside JW. Pathological investigation of the first donor and recipient pair linked by blood transfusion-associated variant Creutzfeldt-Jakob disease infection. Neuropathol Appl Neurobiol 2009, 35:433-6.
25. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004, 364:527-9.
26. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2008, 144:14-23.
27. Millar C, Connor N, Dolan G. Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with bleeding disorders. Haemophilia 2010, 16:305-315.
28. Gregori L, McCombie N, Palmar D. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004, 364:529-31.
29. Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Haematol 1995, 2:472-7.
30. Brown P, Rohwer RG, Dunstan BX. The distribution of infectivity in blood components and plasma derivates in experimental models of transmissible spongiform encephalopathy. Transfusion 1998, 38:810-6.
31. Brown P, Cervenáková L, McShane LM. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999, 39:1169-78.
32. Stenland CJ, Lee DC, Petteway SR, Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002, 42:1497-500.
33. Gregori L, Maring JA, MacAuley C. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 2004, 32:1-10.
34. DH Risk Assessment for VCJD Infectivity in Blood Products 2003, http://www.dnv.com/binaries/vCJD_Update_Report_tcm4-74414.pdf, Available at (Accessed 14th May 2010)
35. Variant CJD and Plasma products 2004, http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733818681?p = 1191942152861, Available at (Accessed 14th May 2010)
36. Lee CA, Ironside JW, Bell JE. Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost 1998, 80:909-11.
37. Brown P. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007, 13(Suppl. 5):33-40.
38. http://www.analytica_world.com/news/e/108609/, Available at (Accessed 14th May 2010)